Veterinary Medicines

Bovilis INtranasal RSP Live nasal spray, lyophilisate and solvent for suspension for cattle

Authorised
  • Bovine parainfluenza virus 3, strain INT2-2013, Live
  • Bovine respiratory syncytial virus, strain Jencine-2013, Live
Download as PDF

Product identification

Medicine name:
Bovilis INtranasal RSP Live nasal spray, lyophilisate and solvent for suspension for cattle
Bovilis RSP Live Vet. lyofilisat og væske til nesespray, suspensjon til storfe
Active substance:
  • Bovine parainfluenza virus 3, strain INT2-2013, Live
  • Bovine respiratory syncytial virus, strain Jencine-2013, Live
Target species:
  • Cattle
Route of administration:
  • Nasal use

Product details

Active substance and strength:
  • Bovine parainfluenza virus 3, strain INT2-2013, Live
    63095.70
    unit(s)
    /
    1.00
    Dose
  • Bovine respiratory syncytial virus, strain Jencine-2013, Live
    100000.00
    unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Nasal spray, suspension
Withdrawal period by route of administration:
  • Nasal use
    • Cattle
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AD07
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Package description:
  • Cardboard box with 50 doses of lyophilisate and cardboard box with 100 ml of solvent
  • Cardboard box with 25 doses of lyophilisate and cardboard box with 50 ml of solvent
  • Cardboard box 5 x 5 doses of lyophilisate and 5 x 10 ml of solvent
  • Cardboard box 5 x 10 doses of lyophilisate and 5 x 20 ml of solvent
  • Cardboard box with 20 doses of lyophilisate and cardboard box with 40 ml of solvent
  • Cardboard box with 1 dose of lyophilisate and 2 ml of solvent.
  • Cardboard box 5 x 1 dose of lyophilisate and 5 x 2 ml of solvent
  • Cardboard box 5 doses of lyophilisate and 10 ml of solvent.
  • Cardboard box 10 doses of lyophilisate and 20 ml of solvent.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
This information is not available for this product.
Manufacturing sites for batch release:
  • INTERVET INTERNATIONAL B.V.
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 18-12322
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0257/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 26/04/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 26/04/2024
Download

Combined File of all Documents

English (PDF)
Published on: 25/03/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."